Novartis/$NVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Ticker
$NVS
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Basel, Switzerland
Employees
75,883
ISIN
US66987V1098
Website
Novartis Metrics
BasicAdvanced
$238B
18.98
$6.38
0.53
$2.60
2.15%
Price and volume
Market cap
$238B
Beta
0.53
52-week high
$121.24
52-week low
$96.06
Average daily volume
1.3M
Dividend rate
$2.60
Financial strength
Current ratio
0.794
Quick ratio
0.502
Long term debt to equity
60.405
Total debt to equity
81.322
Dividend payout ratio (TTM)
60.27%
Interest coverage (TTM)
16.83%
Profitability
EBITDA (TTM)
22,086
Gross margin (TTM)
75.68%
Net profit margin (TTM)
24.16%
Operating margin (TTM)
33.35%
Effective tax rate (TTM)
13.80%
Revenue per employee (TTM)
$700,000
Management effectiveness
Return on assets (TTM)
11.42%
Return on equity (TTM)
32.89%
Valuation
Price to earnings (TTM)
18.977
Price to revenue (TTM)
4.546
Price to book
4.91
Price to tangible book (TTM)
-13.39
Price to free cash flow (TTM)
16.208
Free cash flow yield (TTM)
6.17%
Free cash flow per share (TTM)
746.62%
Dividend yield (TTM)
2.15%
Forward dividend yield
2.15%
Growth
Revenue change (TTM)
11.50%
Earnings per share change (TTM)
-13.29%
3-year revenue growth (CAGR)
0.14%
10-year revenue growth (CAGR)
0.14%
3-year earnings per share growth (CAGR)
-15.93%
10-year earnings per share growth (CAGR)
-2.53%
3-year dividend per share growth (CAGR)
4.34%
10-year dividend per share growth (CAGR)
3.97%
What the Analysts think about Novartis
Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Bulls say / Bears say
Novartis has raised its medium-term sales target, now expecting revenue to grow 6% annually through 2028, driven by strong demand for new cancer and immunological disease medicines. (bloomberg.com)
The company has committed to investing $490 million by 2025 in research and development for diseases including malaria, dengue, leishmaniasis, and Chagas, indicating a strong pipeline for future growth. (reuters.com)
Novartis has launched Borealis Biosciences, a biotech company focused on developing RNA therapeutics for kidney diseases, with $150 million in Series A financing, showcasing its commitment to innovative treatments. (delveinsight.com)
Sales of Novartis's heart failure medication Entresto fell short of expectations in the last quarter, raising concerns about the performance of key products. (bloomberg.com)
The company's prostate cancer treatment, Pluvicto, faced supply constraints leading to weaker-than-expected sales, which could impact revenue growth. (bloomberg.com)
Goldman Sachs maintained a 'Hold' rating on Novartis, indicating potential concerns about the company's growth prospects. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Jun 2025.
Novartis Financial Performance
Revenues and expenses
Novartis Earnings Performance
Company profitability
Novartis News
AllArticlesVideos
7 Killer European Stocks To Buy In July
24/7 Wall Street·2 days ago
Final Trades: Novartis, Sixth Street, Amazon and the IYF
CNBC Television·5 days ago
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novartis stock?
Novartis (NVS) has a market cap of $238B as of July 01, 2025.
What is the P/E ratio for Novartis stock?
The price to earnings (P/E) ratio for Novartis (NVS) stock is 18.98 as of July 01, 2025.
Does Novartis stock pay dividends?
Yes, the Novartis (NVS) stock pays dividends to shareholders. As of July 01, 2025, the dividend rate is $2.59609 and the yield is 2.15%. Novartis has a payout ratio of 60.27% on a trailing twelve-month basis.
When is the next Novartis dividend payment date?
The next Novartis (NVS) dividend payment date is unconfirmed.
What is the beta indicator for Novartis?
Novartis (NVS) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.